United States Spine Osteoarthritis Pain Drug Market Report & Forecast 2021-2027

United States Spine Osteoarthritis Pain Drug Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Spine Osteoarthritis Pain Drug Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Spine Osteoarthritis Pain Drug Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Spine Osteoarthritis Pain Drug Overall Market Size
2.1 United States Spine Osteoarthritis Pain Drug Market Size: 2021 VS 2027
2.2 United States Spine Osteoarthritis Pain Drug Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Spine Osteoarthritis Pain Drug Sales: 2016-2027
3 Company Landscape
3.1 Top Spine Osteoarthritis Pain Drug Players in United States Market
3.2 Top United States Spine Osteoarthritis Pain Drug Companies Ranked by Revenue
3.3 United States Spine Osteoarthritis Pain Drug Revenue by Companies
3.4 United States Spine Osteoarthritis Pain Drug Sales by Companies
3.5 United States Spine Osteoarthritis Pain Drug Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Spine Osteoarthritis Pain Drug Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Spine Osteoarthritis Pain Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Spine Osteoarthritis Pain Drug Players in United States Market
3.8.1 List of Tier 1 Spine Osteoarthritis Pain Drug Companies in United States
3.8.2 List of Tier 2 and Tier 3 Spine Osteoarthritis Pain Drug Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Spine Osteoarthritis Pain Drug Market Size Markets, 2021 & 2027
4.1.2 Oral
4.1.3 Injection
4.1.4 External
4.2 By Type - United States Spine Osteoarthritis Pain Drug Revenue & Forecasts
4.2.1 By Type - United States Spine Osteoarthritis Pain Drug Revenue, 2016-2021
4.2.2 By Type - United States Spine Osteoarthritis Pain Drug Revenue, 2022-2027
4.2.3 By Type - United States Spine Osteoarthritis Pain Drug Revenue Market Share, 2016-2027
4.3 By Type - United States Spine Osteoarthritis Pain Drug Sales & Forecasts
4.3.1 By Type - United States Spine Osteoarthritis Pain Drug Sales, 2016-2021
4.3.2 By Type - United States Spine Osteoarthritis Pain Drug Sales, 2022-2027
4.3.3 By Type - United States Spine Osteoarthritis Pain Drug Sales Market Share, 2016-2027
4.4 By Type - United States Spine Osteoarthritis Pain Drug Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Spine Osteoarthritis Pain Drug Market Size, 2021 & 2027
5.1.2 Medical Care
5.1.3 Personal Care
5.2 By Application - United States Spine Osteoarthritis Pain Drug Revenue & Forecasts
5.2.1 By Application - United States Spine Osteoarthritis Pain Drug Revenue, 2016-2021
5.2.2 By Application - United States Spine Osteoarthritis Pain Drug Revenue, 2022-2027
5.2.3 By Application - United States Spine Osteoarthritis Pain Drug Revenue Market Share, 2016-2027
5.3 By Application - United States Spine Osteoarthritis Pain Drug Sales & Forecasts
5.3.1 By Application - United States Spine Osteoarthritis Pain Drug Sales, 2016-2021
5.3.2 By Application - United States Spine Osteoarthritis Pain Drug Sales, 2022-2027
5.3.3 By Application - United States Spine Osteoarthritis Pain Drug Sales Market Share, 2016-2027
5.4 By Application - United States Spine Osteoarthritis Pain Drug Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Overview
6.1.3 Pfizer Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.1.4 Pfizer Spine Osteoarthritis Pain Drug Product Description
6.1.5 Pfizer Recent Developments
6.2 Johnson and Johnson
6.2.1 Johnson and Johnson Corporation Information
6.2.2 Johnson and Johnson Overview
6.2.3 Johnson and Johnson Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.2.4 Johnson and Johnson Spine Osteoarthritis Pain Drug Product Description
6.2.5 Johnson and Johnson Recent Developments
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Overview
6.3.3 GlaxoSmithKline Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.3.4 GlaxoSmithKline Spine Osteoarthritis Pain Drug Product Description
6.3.5 GlaxoSmithKline Recent Developments
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Overview
6.4.3 Bayer Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.4.4 Bayer Spine Osteoarthritis Pain Drug Product Description
6.4.5 Bayer Recent Developments
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Overview
6.5.3 Eli Lilly Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.5.4 Eli Lilly Spine Osteoarthritis Pain Drug Product Description
6.5.5 Eli Lilly Recent Developments
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Overview
6.6.3 Novartis Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.6.4 Novartis Spine Osteoarthritis Pain Drug Product Description
6.6.5 Novartis Recent Developments
6.7 Sanofi
6.7.1 Sanofi Corporation Information
6.7.2 Sanofi Overview
6.7.3 Sanofi Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.7.4 Sanofi Spine Osteoarthritis Pain Drug Product Description
6.7.5 Sanofi Recent Developments
6.8 Horizon Pharma
6.8.1 Horizon Pharma Corporation Information
6.8.2 Horizon Pharma Overview
6.8.3 Horizon Pharma Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.8.4 Horizon Pharma Spine Osteoarthritis Pain Drug Product Description
6.8.5 Horizon Pharma Recent Developments
6.9 Abbott
6.9.1 Abbott Corporation Information
6.9.2 Abbott Overview
6.9.3 Abbott Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.9.4 Abbott Spine Osteoarthritis Pain Drug Product Description
6.9.5 Abbott Recent Developments
6.10 Mylan
6.10.1 Mylan Corporation Information
6.10.2 Mylan Overview
6.10.3 Mylan Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.10.4 Mylan Spine Osteoarthritis Pain Drug Product Description
6.10.5 Mylan Recent Developments
6.11 Daiichi Sankyo
6.11.1 Daiichi Sankyo Corporation Information
6.11.2 Daiichi Sankyo Overview
6.11.3 Daiichi Sankyo Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.11.4 Daiichi Sankyo Spine Osteoarthritis Pain Drug Product Description
6.11.5 Daiichi Sankyo Recent Developments
6.12 TEVA
6.12.1 TEVA Corporation Information
6.12.2 TEVA Overview
6.12.3 TEVA Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.12.4 TEVA Spine Osteoarthritis Pain Drug Product Description
6.12.5 TEVA Recent Developments
6.13 Almatica Pharma
6.13.1 Almatica Pharma Corporation Information
6.13.2 Almatica Pharma Overview
6.13.3 Almatica Pharma Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.13.4 Almatica Pharma Spine Osteoarthritis Pain Drug Product Description
6.13.5 Almatica Pharma Recent Developments
6.14 Astellas Pharma
6.14.1 Astellas Pharma Corporation Information
6.14.2 Astellas Pharma Overview
6.14.3 Astellas Pharma Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.14.4 Astellas Pharma Spine Osteoarthritis Pain Drug Product Description
6.14.5 Astellas Pharma Recent Developments
6.15 Tide Pharmaceutical
6.15.1 Tide Pharmaceutical Corporation Information
6.15.2 Tide Pharmaceutical Overview
6.15.3 Tide Pharmaceutical Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.15.4 Tide Pharmaceutical Spine Osteoarthritis Pain Drug Product Description
6.15.5 Tide Pharmaceutical Recent Developments
6.16 Iroko Pharmaceuticals
6.16.1 Iroko Pharmaceuticals Corporation Information
6.16.2 Iroko Pharmaceuticals Overview
6.16.3 Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.16.4 Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Product Description
6.16.5 Iroko Pharmaceuticals Recent Developments
6.17 Hengrui Pharmaceutical
6.17.1 Hengrui Pharmaceutical Corporation Information
6.17.2 Hengrui Pharmaceutical Overview
6.17.3 Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.17.4 Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Product Description
6.17.5 Hengrui Pharmaceutical Recent Developments
6.18 Abiogen Pharma
6.18.1 Abiogen Pharma Corporation Information
6.18.2 Abiogen Pharma Overview
6.18.3 Abiogen Pharma Spine Osteoarthritis Pain Drug Sales and Revenue in United States Market (2016-2021)
6.18.4 Abiogen Pharma Spine Osteoarthritis Pain Drug Product Description
6.18.5 Abiogen Pharma Recent Developments
7 United States Spine Osteoarthritis Pain Drug Production Capacity, Analysis
7.1 United States Spine Osteoarthritis Pain Drug Production Capacity, 2016-2027
7.2 Spine Osteoarthritis Pain Drug Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Spine Osteoarthritis Pain Drug Supply Chain Analysis
9.1 Spine Osteoarthritis Pain Drug Industry Value Chain
9.2 Spine Osteoarthritis Pain Drug Upstream Market
9.3 Spine Osteoarthritis Pain Drug Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Spine Osteoarthritis Pain Drug Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Spine Osteoarthritis Pain Drug in United States Market
Table 2. Top Spine Osteoarthritis Pain Drug Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Spine Osteoarthritis Pain Drug Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Spine Osteoarthritis Pain Drug Revenue Share by Companies, 2016-2021
Table 5. United States Spine Osteoarthritis Pain Drug Sales by Companies, (K Units), 2016-2021
Table 6. United States Spine Osteoarthritis Pain Drug Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Spine Osteoarthritis Pain Drug Price (2016-2021) & (USD/Unit)
Table 8. Manufacturers Spine Osteoarthritis Pain Drug Product Type
Table 9. List of Tier 1 Spine Osteoarthritis Pain Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Spine Osteoarthritis Pain Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Oral
Table 12. Major Manufacturers of Injection
Table 13. By Type - United States Spine Osteoarthritis Pain Drug Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Spine Osteoarthritis Pain Drug Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Spine Osteoarthritis Pain Drug Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Spine Osteoarthritis Pain Drug Sales (K Units), 2016-2021
Table 17. By Type - United States Spine Osteoarthritis Pain Drug Sales (K Units), 2022-2027
Table 18. By Application - United States Spine Osteoarthritis Pain Drug Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Spine Osteoarthritis Pain Drug Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Spine Osteoarthritis Pain Drug Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Spine Osteoarthritis Pain Drug Sales (K Units), 2016-2021
Table 22. By Application - United States Spine Osteoarthritis Pain Drug Sales (K Units), 2022-2027
Table 23. Pfizer Corporation Information
Table 24. Pfizer Description and Major Businesses
Table 25. Pfizer Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 26. Pfizer Spine Osteoarthritis Pain Drug Product
Table 27. Pfizer Recent Developments
Table 28. Johnson and Johnson Corporation Information
Table 29. Johnson and Johnson Description and Major Businesses
Table 30. Johnson and Johnson Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 31. Johnson and Johnson Spine Osteoarthritis Pain Drug Product
Table 32. Johnson and Johnson Recent Developments
Table 33. GlaxoSmithKline Corporation Information
Table 34. GlaxoSmithKline Description and Major Businesses
Table 35. GlaxoSmithKline Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 36. GlaxoSmithKline Spine Osteoarthritis Pain Drug Product
Table 37. GlaxoSmithKline Recent Developments
Table 38. Bayer Corporation Information
Table 39. Bayer Description and Major Businesses
Table 40. Bayer Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 41. Bayer Spine Osteoarthritis Pain Drug Product
Table 42. Bayer Recent Developments
Table 43. Eli Lilly Corporation Information
Table 44. Eli Lilly Description and Major Businesses
Table 45. Eli Lilly Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 46. Eli Lilly Spine Osteoarthritis Pain Drug Product
Table 47. Eli Lilly Recent Developments
Table 48. Novartis Corporation Information
Table 49. Novartis Description and Major Businesses
Table 50. Novartis Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 51. Novartis Spine Osteoarthritis Pain Drug Product
Table 52. Novartis Recent Developments
Table 53. Sanofi Corporation Information
Table 54. Sanofi Description and Major Businesses
Table 55. Sanofi Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 56. Sanofi Spine Osteoarthritis Pain Drug Product
Table 57. Sanofi Recent Developments
Table 58. Horizon Pharma Corporation Information
Table 59. Horizon Pharma Description and Major Businesses
Table 60. Horizon Pharma Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 61. Horizon Pharma Spine Osteoarthritis Pain Drug Product
Table 62. Horizon Pharma Recent Developments
Table 63. Abbott Corporation Information
Table 64. Abbott Description and Major Businesses
Table 65. Abbott Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 66. Abbott Spine Osteoarthritis Pain Drug Product
Table 67. Abbott Recent Developments
Table 68. Mylan Corporation Information
Table 69. Mylan Description and Major Businesses
Table 70. Mylan Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 71. Mylan Spine Osteoarthritis Pain Drug Product
Table 72. Mylan Recent Developments
Table 73. Daiichi Sankyo Corporation Information
Table 74. Daiichi Sankyo Description and Major Businesses
Table 75. Daiichi Sankyo Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 76. Daiichi Sankyo Spine Osteoarthritis Pain Drug Product
Table 77. Daiichi Sankyo Recent Developments
Table 78. TEVA Corporation Information
Table 79. TEVA Description and Major Businesses
Table 80. TEVA Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 81. TEVA Spine Osteoarthritis Pain Drug Product
Table 82. TEVA Recent Developments
Table 83. Almatica Pharma Corporation Information
Table 84. Almatica Pharma Description and Major Businesses
Table 85. Almatica Pharma Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 86. Almatica Pharma Spine Osteoarthritis Pain Drug Product
Table 87. Almatica Pharma Recent Developments
Table 88. Astellas Pharma Corporation Information
Table 89. Astellas Pharma Description and Major Businesses
Table 90. Astellas Pharma Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 91. Astellas Pharma Spine Osteoarthritis Pain Drug Product
Table 92. Astellas Pharma Recent Developments
Table 93. Tide Pharmaceutical Corporation Information
Table 94. Tide Pharmaceutical Description and Major Businesses
Table 95. Tide Pharmaceutical Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 96. Tide Pharmaceutical Spine Osteoarthritis Pain Drug Product
Table 97. Tide Pharmaceutical Recent Developments
Table 98. Iroko Pharmaceuticals Corporation Information
Table 99. Iroko Pharmaceuticals Description and Major Businesses
Table 100. Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 101. Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Product
Table 102. Iroko Pharmaceuticals Recent Developments
Table 103. Hengrui Pharmaceutical Corporation Information
Table 104. Hengrui Pharmaceutical Description and Major Businesses
Table 105. Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 106. Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Product
Table 107. Hengrui Pharmaceutical Recent Developments
Table 108. Abiogen Pharma Corporation Information
Table 109. Abiogen Pharma Description and Major Businesses
Table 110. Abiogen Pharma Spine Osteoarthritis Pain Drug Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021)
Table 111. Abiogen Pharma Spine Osteoarthritis Pain Drug Product
Table 112. Abiogen Pharma Recent Developments
Table 113. Spine Osteoarthritis Pain Drug Production Capacity (K Units) of Key Manufacturers in United States Market, 2019-2021 (K Units)
Table 114. United States Spine Osteoarthritis Pain Drug Capacity Market Share of Key Manufacturers, 2019-2021
Table 115. Spine Osteoarthritis Pain Drug Market Opportunities & Trends in United States Market
Table 116. Spine Osteoarthritis Pain Drug Market Drivers in United States Market
Table 117. Spine Osteoarthritis Pain Drug Market Restraints in United States Market
Table 118. Spine Osteoarthritis Pain Drug Raw Materials
Table 119. Spine Osteoarthritis Pain Drug Raw Materials Suppliers in United States Market
Table 120. Typical Spine Osteoarthritis Pain Drug Downstream
Table 121. Spine Osteoarthritis Pain Drug Downstream Clients in United States Market
Table 122. Spine Osteoarthritis Pain Drug Distributors and Sales Agents in United States Market
List of Figures
Figure 1. Spine Osteoarthritis Pain Drug Product Picture
Figure 2. Spine Osteoarthritis Pain Drug Segment by Type
Figure 3. Spine Osteoarthritis Pain Drug Segment by Application
Figure 4. United States Spine Osteoarthritis Pain Drug Market Overview: 2020
Figure 5. United States Spine Osteoarthritis Pain Drug Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Spine Osteoarthritis Pain Drug Revenue, 2016-2027 (US$, Mn)
Figure 7. Spine Osteoarthritis Pain Drug Sales in United States Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Spine Osteoarthritis Pain Drug Revenue in 2020
Figure 9. Oral Product Picture
Figure 10. Injection Product Picture
Figure 11. External Product Picture
Figure 12. By Type - United States Spine Osteoarthritis Pain Drug Sales Market Share, 2016-2027
Figure 13. By Type - United States Spine Osteoarthritis Pain Drug Revenue Market Share, 2016-2027
Figure 14. By Type - United States Spine Osteoarthritis Pain Drug Price (USD/Unit), 2016-2027
Figure 15. Medical Care
Figure 16. Personal Care
Figure 17. By Application - United States Spine Osteoarthritis Pain Drug Sales Market Share, 2016-2027
Figure 18. By Application - United States Spine Osteoarthritis Pain Drug Revenue Market Share, 2016-2027
Figure 19. By Application - United States Spine Osteoarthritis Pain Drug Price (USD/Unit), 2016-2027
Figure 20. Pfizer Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 21. Johnson and Johnson Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 22. GlaxoSmithKline Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Bayer Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Eli Lilly Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. Novartis Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Sanofi Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Horizon Pharma Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Abbott Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Mylan Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Daiichi Sankyo Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. TEVA Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. Almatica Pharma Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Astellas Pharma Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. Tide Pharmaceutical Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 37. Abiogen Pharma Spine Osteoarthritis Pain Drug Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. United States Spine Osteoarthritis Pain Drug Production Capacity (K Units), 2016-2027
Figure 39. Spine Osteoarthritis Pain Drug Industry Value Chain
Figure 40. Marketing Channels

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs